Michael J. Grant

Michael J. Grant

Auto-generated profile, based on publicly available information

Michael J. Grant

Department of Medicine (Section of Medical Oncology), Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA; Yale Cancer Center, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2024 in Chest
Verified
Journal Article
Closed access
FDFrank C. Detterbeck
Frank C. Detterbeck
GWGavitt A. Woodard
Gavitt A. Woodard
ABAnna S. Bader
Anna S. Bader
SDSanja Dacic
Sanja Dacic
MGMichael J. Grant
Michael J. Grant
LTLynn T. Tanoue
Lynn T. Tanoue

13 March 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MGMichael J. Grant
Michael J. Grant
JAJacqueline V. Aredo
Jacqueline V. Aredo
JSJacqueline H. Starrett
Jacqueline H. Starrett
PSPaul Stockhammer
Paul Stockhammer
IRIris K. van Alderwerelt van Rosenburgh
Iris K. van Alderwerelt van Rosenburgh
SGSarah B. Goldberg
Sarah B. Goldberg
Purpose: The uncommon EGFR exon 19 deletion (ex19del), L747_A750>P, demonstrates reduced sensitivity to osimertinib compared with the common ex19del, E746_A750del in preclinical models. The clinical efficacy of osimertinib in patients with non–small cell lung cancer harboring L747_A750>P and other uncommon ex19dels is not known. Experimental Design: The AACR GENIE database was interrogated to characterize the frequency of individual ex19dels relative to other variants, and a multicenter retrospective cohort was used to compare clinical outcomes for patients with tumors harboring E746_A750del, L747_A750>P, and other uncommon ex19dels who received osimertinib in the first line (1L) or in second or later lines of therapy and were T790M+ (≥2L). Results: ex19dels comprised 45% of EGFR mutations, with 72 distinct variants ranging in frequency from 28.1% (E746_A750del) to 0.03%, with L747_A750>P representing 1.8% of the EGFR mutant cohort. In our multi-institutional cohort (N = 200), E746_A750del was associated with significantly prolonged progression-free survival (PFS) with 1L osimertinib versus L747_A750>P [median 21.3 months (95% confidence interval, 17.0–31.7) vs. 11.7 months (10.8–29.4); adjusted HR 0.52 (0.28–0.98); P = 0.043]. Osimertinib efficacy in patients with other uncommon ex19dels varied on the basis of the specific mutation present. Conclusions: The ex19del L747_A750>P is associated with inferior PFS compared with the common E746_A750del mutation in patients treated with 1L osimertinib. Understanding differences in osimertinib efficacy among EGFR ex19del subtypes could alter management of these patients in the future.

2 April 2026 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PSPaul Stockhammer
Paul Stockhammer
TZTalal El Zarif
Talal El Zarif
JSJacob L. Schillo
Jacob L. Schillo
FLFangyong Li
Fangyong Li
SGSarah B. Goldberg
Sarah B. Goldberg
MGMichael J. Grant
Michael J. Grant

5 April 2023 in Hematology/Oncology Clinics of North America
Verified
Journal Article
Closed access
MGMichael J. Grant
Michael J. Grant
GWGavitt A. Woodard
Gavitt A. Woodard
SGSarah B. Goldberg
Sarah B. Goldberg

12 March 2018 in Case Reports in Transplantation
Verified
Journal Article
Open access
PDF file
MGMichael J. Grant
Michael J. Grant
MHMitchell E. Horwitz
Mitchell E. Horwitz
Gastric antral vascular ectasia or “watermelon stomach” is a significant cause of nonvariceal upper GI bleeding and is characterized by red, tortuous ectatic vessels along longitudinal folds in the gastric antrum. The existing literature links GAVE to patients with cirrhosis, scleroderma, bone marrow transplantation, and chronic renal failure among other associations, but its pathophysiology remains ill-defined. Over 30 cases of hematopoietic stem cell transplant-related GAVE (HSCT-GAVE) have been reported in the literature to date and there are likely many more that go undiagnosed or are attributed to another cause of upper gastrointestinal bleeding. Interestingly, a busulfan-containing conditioning regimen has been the primary factor implicated in the etiology of HSCT-GAVE because this was common to all cases in the literature to date. Here, we present the first case of HSCT-GAVE in a patient that was treated with a non-busulfan-containing conditioning regimen. We propose a link between chronic GVHD and the development of HSCT-GAVE that is supported by a similar development of GAVE in patients with systemic sclerosis.

15 January 2021
Verified
Journal Article
Closed access
SUSerhan Unlu
Serhan Unlu
MGMichael J Grant
Michael J Grant
SGScott Gettinger
Scott Gettinger
AAAdebowale Adeniran
Adebowale Adeniran
HKHarriet M Kluger
Harriet M Kluger